When did Aquestive Therapeutics, Inc. report Q4 2024 earnings?

Aquestive Therapeutics, Inc. (AQST) reported Q4 2024 earnings on March 5, 2025 after market close.

What were Aquestive Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Aquestive Therapeutics, Inc. reported revenue of $11.9M and diluted EPS of $-0.19 for Q4 2024.

Did Aquestive Therapeutics, Inc. beat estimates in Q4 2024?

Revenue missed the consensus estimate of $13.1M by $1.2M. EPS missed the consensus estimate of $-0.14 by $0.05.

Where can I find Aquestive Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001628280-25-010506) directly on SEC EDGAR. The filing index links above go to sec.gov.

Aquestive Therapeutics, Inc. AQST Q4 2024 Annual earnings

Reported March 5, 2025 · After market close

Revenue$11.9MMiss by $1.2M Diluted EPS-$0.19Miss by $0.05

Revenue estimate$13.1M

EPS estimate-$0.14

Next report

Aug 10, 2026 (In 4 weeks)

Revenue estimate$11.4M

EPS estimate-$0.10

Financials

Q4 2024

Income statement

See full

Revenue$11.9M-10.1%

Gross profit$7.3M-13.8%

Operating income-$13.6M-247%

Net income-$17.1M-110%

EPS (diluted)-$0.19-46.2%

Balance sheet

See full

Cash & equivalents$71.5M+200%

Total debt$50.6M+51.2%

Total equity-$60.2M+43.5%

Total assets$101.4M+76.6%

Cash flow

See full

Operating cash flow-$6.5M-31.3%

CapEx$15.0K-6.3%

Free cash flow-$6.5M-31.2%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$324.59M+141%

Enterprise value$303.67M+110%

P/S5.6×+3.0×

Profitability

See full

Gross margin69%+10.1pp

Operating margin-53.5%+202pp

Net margin-76.7%-103pp

FCF margin-62.4%-89.8pp

Returns & leverage

See full

Current ratio4.7×+2.4×

Segments

By product

See full

Manufacture and supply revenue$10.7M—

License and royalty revenue a$831.0K—

Co-development and research fees$274.0K—

Proprietary product revenue, net$98.0K—

By segment

See full

Reportable Segment$11.9M-6.2%

By geography

See full

United States$9.3M—

Versus estimates

Revenue

Q1 2026$14.4MBeat by $3.6M Q4 2025$13.0MMiss by $271.4K Q3 2025$12.8MMiss by $136.5K Q2 2025$10.0MMiss by $2.2M Q1 2025$8.7MMiss by $3.5M

Q4 2024$11.9MMiss by $1.2M

Diluted EPS

Q1 2026-$0.07Beat by $0.07 Q4 2025-$0.26Miss by $0.13 Q3 2025-$0.14Miss by $0.03 Q2 2025-$0.14Beat by $0.04 Q1 2025-$0.24Miss by $0.07

Q4 2024-$0.19Miss by $0.05

Ask the moment Aquestive Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Aquestive Therapeutics, Inc. report Q4 2024 earnings?: Aquestive Therapeutics, Inc. (AQST) reported Q4 2024 earnings on March 5, 2025 after market close.
What were Aquestive Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Aquestive Therapeutics, Inc. reported revenue of $11.9M and diluted EPS of $-0.19 for Q4 2024.
Did Aquestive Therapeutics, Inc. beat estimates in Q4 2024?: Revenue missed the consensus estimate of $13.1M by $1.2M. EPS missed the consensus estimate of $-0.14 by $0.05.
Where can I find Aquestive Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001628280-25-010506) directly on SEC EDGAR. The filing index links above go to sec.gov.